Revolutionary advancements in blood cancer treatment, from targeted therapy to gene editing, promise more effective and ...

Modeling data indicated that the greater predicted reduction of FeNO observed with verekitug, compared with published data for tezepelumab, is potentially driven by lower expression levels of the TSLP ...

Epcoritamab demonstrated a median CR of 36 months and a median progression-free survival of 37 months in LBCL patients.